These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12669474)

  • 1. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
    Kennett RH
    Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
    Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
    Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma.
    Oosterwijk E; Debruyne FM; Schalken JA
    Semin Oncol; 1995 Feb; 22(1):34-41. PubMed ID: 7855618
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
    Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.
    Brouwers AH; Buijs WC; Mulders PF; de Mulder PH; van den Broek WJ; Mala C; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7178s-7186s. PubMed ID: 16203819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
    Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
    Loh A; Sgouros G; O'Donoghue JA; Deland D; Puri D; Capitelli P; Humm JL; Larson SM; Old LJ; Divgi CR
    J Nucl Med; 1998 Mar; 39(3):484-9. PubMed ID: 9529296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
    Sheikh N
    Curr Opin Mol Ther; 2003 Aug; 5(4):428-32. PubMed ID: 14513687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.
    Oosterwijk E; Debruyne FM
    World J Urol; 1995; 13(3):186-90. PubMed ID: 7550393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
    Bleumer I; Oosterwijk E; Oosterwijk-Wakka JC; Völler MC; Melchior S; Warnaar SO; Mala C; Beck J; Mulders PF
    J Urol; 2006 Jan; 175(1):57-62. PubMed ID: 16406869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
    Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
    Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.